Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. - Wikidata - wikimedia - TriplyDB

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

http://www.wikidata.org/entity/Q33558073

about

Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery Macular grid laser photocoagulation for branch retinal vein occlusion Anti-vascular endothelial growth factor for diabetic macular oedema Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials Clinical Trials in Branch Retinal Vein Occlusion The role of aflibercept in the management of diabetic macular edema Current perspectives on ranibizumab An Endovascular Cannulation Needle with an Internal Wire for the Fragmentation of Thrombi in Retinal Vein Occlusion EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.Evaluation of hyperreflective foci as a prognostic factor of visual outcome in retinal vein occlusion.Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.Role of inflammation in previously untreated macular edema with branch retinal vein occlusion Patient's self-recognition of reduced visual acuity due to recurrence of macular edema and prompt visitation to the hospital in retinal vein occlusion.Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study An introduction to patient-reported outcome measures in ophthalmic research.Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update.Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.Ranibizumab for the treatment of degenerative ocular conditions.Economic considerations of macular edema therapies The burden of disease of retinal vein occlusion: review of the literature.Treatment of macular edema due to retinal vein occlusions.Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion.Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.Evaluation of masking study participants to intravitreal injections in a randomized clinical trial High intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusion Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40 Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting.Antiangiogenic therapy for ischemic retinopathies.Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners Short-duration focal pattern grid photocoagulation for macular edema secondary to branch retinal vein occlusion.

P2860

Q24186464-D6385ECD-D7B8-4A09-969D-073D29A107CF Q24187991-BFCD2ABD-5C54-427F-8F0B-0DABB429FCC1 Q24193083-BBAE512D-CF12-40BF-BB94-8F44A8B2A329 Q24200772-01CEBFCB-D0C7-4D9F-B219-19CB3A9634F6 Q24201821-E389A68F-DFCF-4558-9A81-FA1AC2C377BB Q24202071-545647F3-62D3-4934-B9A1-9442EEEED73F Q24234750-D34DF20D-C104-49E4-AE93-1892671D33BA Q26750459-0436BBEB-C843-4CEA-817A-DE183AAC932D Q26767092-F6FADEE8-F5B8-4BC3-9687-D468EBF3A547 Q26798348-623451CC-21A6-4C01-818A-D4600ED6F84C Q28082383-39E18AAD-A11B-4CB6-8556-84DDF3A78FA0 Q30372587-9FB68760-B7F9-44A0-99B8-B4C7082E4855 Q30490419-4A0E09A2-A09B-47AE-BA12-D648DB27F844 Q31131691-6D059D32-1F4C-42F5-BDE1-CB91CDF6E7D4 Q31155420-8998F2FB-9743-423A-A0FF-FB0A81273D64 Q33607767-335052F0-7B82-4E93-906D-1A325D313AAF Q33648485-DE54EF91-6A02-4419-984A-9B7360741D53 Q33656127-37179910-1636-42A6-9479-88F207AFD153 Q33686686-8614423E-ACDB-40C4-876D-2DE059DB8E77 Q33701661-5DC09864-94F2-4B5D-87A3-D3278014E369 Q33759121-E5FEDC56-8240-458C-AF76-B5433A8A8862 Q33770558-F1BCB40B-3A3E-4592-86CB-B130E2AE419B Q33795991-C5170E7B-5D5C-4261-888E-EBE93B30603C Q33828254-5F00674B-86EF-4692-809B-6BCF19FD1D95 Q33831237-C4E2CEAC-2B2F-4E18-9C45-AA0DDFAA3785 Q33878122-C60C8F97-C36A-4E40-9CF3-5CFC5FF23806 Q33890866-ECC63C5F-96B8-49EF-AA47-0A65B4A129BC Q33918085-EF856706-E737-4C29-9544-3ECB900FB0CC Q33993712-ED6BF422-5351-4C4D-9328-C975E35DA17C Q34088274-94509A4D-72CD-4FF7-B03C-088C530FEFD5 Q34115840-09834D4E-E1D2-4C32-BDFA-A97FE4A8F635 Q34139793-413C8DB0-B605-4190-94FF-D0C08F917A2E Q34158304-E6520A11-684C-4F24-BF9A-195493B90461 Q34200359-0D1A751F-DA9D-443F-BC12-E6A4954B9184 Q34206455-EB1F3066-4432-4F88-B513-69E032B39318 Q34293412-271DD8C8-5F95-475D-B7AA-2723617A2FA7 Q34295974-C5C4F9D1-BE60-4850-A22B-943A2EAC1DB3 Q34311551-DFFCA741-B4EB-4C91-BD11-DF17C633291F Q34325559-F976C5BB-D0A0-48AB-B50C-4F01AEF8FB6B Q34333307-E42BE122-67E2-453F-BCCE-B43F88A6298E

P2860

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

http://www.wikidata.org/entity/Q33558073

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Ranibizumab for macular edema ...... results of a phase III study.

@ast

Ranibizumab for macular edema ...... results of a phase III study.

@en

Ranibizumab for macular edema ...... results of a phase III study.

@nl

type

label

Ranibizumab for macular edema ...... results of a phase III study.

@ast

Ranibizumab for macular edema ...... results of a phase III study.

@en

Ranibizumab for macular edema ...... results of a phase III study.

@nl

prefLabel

Ranibizumab for macular edema ...... results of a phase III study.

@ast

Ranibizumab for macular edema ...... results of a phase III study.

@en

Ranibizumab for macular edema ...... results of a phase III study.

@nl

P1433

Q33558073-62131280-16AC-444B-ADB9-06038AFC9DD4

P1476

Q33558073-C3CA5237-282B-477B-A458-EDB44669D4BC

P2093

Q33558073-479AA005-A295-4C97-B338-B9DFF27F900D

Q33558073-61AEF8AC-7903-477E-88AC-0FBDAA6CC794

Q33558073-62F7EC20-53EC-49C4-9CD4-BDDCC2322592

Q33558073-69721C32-FBD2-4628-98CD-8FD2626C298D

Q33558073-6AD91566-4C3A-4E99-82DC-D2DD68D72F21

Q33558073-83469D55-5FD5-402B-9F64-0E360FDB5FDB

Q33558073-83785833-B216-4125-A439-4C265B103303

Q33558073-95FDFE39-8712-49BF-AC20-C61F1EFD370A

Q33558073-AFA8516C-474E-42C7-9CD2-43B3C9305920

P304

Q33558073-8A60C8FF-20A1-48B5-BD99-CC4D122668BB

P31

Q33558073-D4323697-52BA-4E99-A2A1-DD1777F11FCC

P356

Q33558073-7849DCE8-A072-4884-99E0-153975635FE5

P433

Q33558073-3F79F536-0A5E-4B42-BECA-D008659DF339

P478

Q33558073-B9C80330-3F55-40AE-B6C1-23F10A658962

P577

Q33558073-3B21C7EB-E1C7-4E16-9CBC-E947CA52668D

P698

Q33558073-E6FE0CF7-AC68-43A2-A997-939D9290C54E

P356

J.OPHTHA.2010.02.021

P1433

P1476

Ranibizumab for macular edema ...... results of a phase III study.

@en

P2093

Amy Chen Rundle

http://www.w3.org/2001/XMLSchema#string

BRAVO Investigators

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Heier

http://www.w3.org/2001/XMLSchema#string

Leonard Feiner

http://www.w3.org/2001/XMLSchema#string

Namrata Saroj

http://www.w3.org/2001/XMLSchema#string

Peter A Campochiaro

http://www.w3.org/2001/XMLSchema#string

Roman G Rubio

http://www.w3.org/2001/XMLSchema#string

Sarah Gray

http://www.w3.org/2001/XMLSchema#string

Wendy Yee Murahashi

http://www.w3.org/2001/XMLSchema#string

P304

1102-1112.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2010.02.021

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20398941

http://www.w3.org/2001/XMLSchema#string